CoChat
Sign Up
Cited by 194

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Challenges and Opportunities of Nanomedicines in Clinical Translation

Zheng, Chunxiong, Li, Mingqiang, Ding, Jianxun·2021·BIO Integration
DOI 10.15212/bioi-2021-0016
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.15212/bioi-2021-0016

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 4 references

Research works printed but not linked: 23

  1. J Wolfram, 2019, Clinical cancer nanomedicine, Nano Today, 25, 85, 10.1016/j.nantod.2019.02.005 · DOI
  2. J Shi, 2017, Cancer nanomedicine: Progress, challenges and opportunities, Nat Rev Cancer, 17, 20, 10.1038/nrc.2016.108 · DOI · Paper page
  3. Y Min, 2015, Clinical translation of nanomedicine, Chem Rev, 115, 11147, 10.1021/acs.chemrev.5b00116 · DOI
  4. DX Sun, 2020, What went wrong with anticancer nanomedicine design and how to make it right, ACS Nano, 14, 12281, 10.1021/acsnano.9b09713 · DOI
  5. M Hay, 2014, Clinical development success rates for investigational drugs, Nat Biotechnol, 32, 40, 10.1038/nbt.2786 · DOI · Paper page
  6. A Wicki, 2015, Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications, J Control Release, 200, 138, 10.1016/j.jconrel.2014.12.030 · DOI
  7. C Zhang, 2020, Progress, challenges, and future of nanomedicine, Nano Today, 35, 10.1016/j.nantod.2020.101008 · DOI
  8. YH Bae, 2020, Advanced drug delivery 2020 and beyond: Perspectives on the future, Adv Drug Del Rev, 158, 4, 10.1016/j.addr.2020.06.018 · DOI
  9. Y Ding, 2020, Investigating the EPR effect of nanomedicines in human renal tumors via ex vivo perfusion strategy, Nano Today, 35, 10.1016/j.nantod.2020.100970 · DOI
  10. J Bourquin, 2018, Biodistribution, clearance, and long-term fate of clinically relevant nanomaterials, Adv Mater, 30, 10.1002/adma.201704307 · DOI
  11. J Ding, 2019, Engineered nanomedicines with enhanced tumor penetration, Nano Today, 29, 10.1016/j.nantod.2019.100800 · DOI
  12. L Wei, 2021, Sequentially stimuli-responsive anticancer nanomedicines, Nanomedicine, 16, 261, 10.2217/nnm-2021-0019 · DOI
  13. C Li, 2020, Innovative Irinotecan-loaded nanomicelles will enter Phase I clinical trial in 2021, The Innovation, 1
  14. Y Zhao, 2019, Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice, Nano Lett, 19, 674, 10.1021/acs.nanolett.8b03644 · DOI
  15. Y Zhao, 2020, Neuroprotective nanoscavenger induces coaggregation of β-amyloid and facilitates its clearance in Alzheimer’s disease brain, CCS Chem, 2316
  16. DJ Irvine, 2020, Enhancing cancer immunotherapy with nanomedicine, Nat Rev Immunol, 20, 321, 10.1038/s41577-019-0269-6 · DOI
  17. AE Nel, 2009, Understanding biophysicochemical interactions at the nano-bio interface, Nat Mater, 8, 543, 10.1038/nmat2442 · DOI · Paper page
  18. S Li, 2020, Oral delivery of bacteria: Basic principles and biomedical applications, J Control Release, 10, 801, 10.1016/j.jconrel.2020.09.011 · DOI
  19. H Hu, 2021, Flash technology-based self-assembly in nanoformulation: Fabrication to biomedical applications, Mater Today, 42, 99, 10.1016/j.mattod.2020.08.019 · DOI
  20. J Xu, 2013, Future of the particle replication in nonwetting templates (PRINT) technology, Angew Chem Int Ed, 52, 6580, 10.1002/anie.201209145 · DOI · Paper page
  21. JM Lim, 2014, Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer, ACS Nano, 8, 6056, 10.1021/nn501371n · DOI
  22. Fong, 2012, Building bridges: Leveraging interdisciplinary collaborations in the development of biomaterials to meet clinical needs, Adv Mater, 24, 4995, 10.1002/adma.201201762 · DOI
  23. TC Roberts, 2020, Advances in oligonucleotide drug delivery, Nat Rev Drug Discov, 19, 673, 10.1038/s41573-020-0075-7 · DOI

Cited by

Sorted by citations

Metadata

Authors
Zheng, C., Li, M., & Ding, J.
Venue
BIO Integration
Publisher
Compuscript, Ltd.
Published
2021
Volume
2
Issue
2
ISSN
  • 2712-0074
  • 2712-0082
DOI
10.15212/bioi-2021-0016
Cited by
194
References
4
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review